FDA grant Fast Track Designation to apitegromab for the treatment of patients with spinal muscular atrophy (SMA)

Apitegromab is a selective inhibitor of the activation of myostatin, a member of the TGFβ superfamily of growth factors, expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength.

Source:

Biospace Inc.